Literature DB >> 1250280

Detection of anti-acetylcholine receptor factors in serum and thymus from patients with myasthenia gravis.

T Mittag, P Kornfeld, A Tormay, C Woo.   

Abstract

Since the blood and thymus of patients with myasthenia gravis may contain inhibitors of neuromuscular transmission that affect acetylcholine receptors of striated muscle, we used denervated rat muscle to test for inhibitors in 43 serums and 18 thymus glands from such patients. Seven per cent of serums inhibited the binding of 125l alpha-bungarotoxin to triton-solubilized receptors; 65 per cent interfered with binding of toxin-labeled receptors to concanavalin-A coupled to Sepharose gel, and 85 per cent formed IgG-receptor complexes detectable by immunoprecipitation. Serum inhibitory activity varied widely among patients with similar clinical manifestations and was not correlated with duration of myasthenia gravis or thymectomy. Among thymus extracts, 44 per cent were inhibitory in the concanavalin-A binding assay, whereas 72 per cent contained anti-receptor IgG. Thus, serums from patients with myasthenia gravis contain more than one anti-receptor factor.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1250280     DOI: 10.1056/NEJM197603252941303

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  29 in total

Review 1.  Immunopathologic events at the endplate in myasthenia gravis.

Authors:  T Ashizawa; S H Appel
Journal:  Springer Semin Immunopathol       Date:  1985

2.  Effects of autoantibodies to the insulin receptor on isolated adipocytes. Studies of insulin binding and insulin action.

Authors:  C R Kahn; K Baird; J S Filier; D B Jarrett
Journal:  J Clin Invest       Date:  1977-11       Impact factor: 14.808

3.  Myasthenia gravis: further electrophysiological and ultrastructural analysis of transmission failure in the mouse passive transfer model.

Authors:  K V Toyka; K L Birnberger; A P Anzil; C Schlegel; U Besinger; A Struppler
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-08       Impact factor: 10.154

Review 4.  Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.

Authors:  Grayson Beecher; Brendan Nicholas Putko; Amanda Nicole Wagner; Zaeem Azfer Siddiqi
Journal:  Drugs       Date:  2019-03       Impact factor: 9.546

5.  Pathogenesis of myasthenia gravis. Acetylcholine receptor-related antigenic determinants in tumor-free thymuses and thymic epithelial tumors.

Authors:  T Kirchner; S Tzartos; F Hoppe; B Schalke; H Wekerle; H K Müller-Hermelink
Journal:  Am J Pathol       Date:  1988-02       Impact factor: 4.307

6.  Serum from patients with pernicious anaemia blocks gastrin stimulation of acid secretion by parietal cells.

Authors:  H J de Aizpurua; B Ungar; B H Toh
Journal:  Clin Exp Immunol       Date:  1985-08       Impact factor: 4.330

7.  [Myasthenic syndrome during penicillamine treatment (author's transl)].

Authors:  F Schumm; M Stöhr
Journal:  Klin Wochenschr       Date:  1978-02-01

8.  Myasthenia gravis: antibodies to acetylcholine receptor in ocular myasthenia gravis.

Authors:  K Oda; Y Ito
Journal:  J Neurol       Date:  1981       Impact factor: 4.849

9.  Anti-acetylcholine receptor antibodies.

Authors:  A Vincent; J Newsom Davis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-07       Impact factor: 10.154

10.  Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis.

Authors:  Ruoyi Jiang; Kenneth B Hoehn; Casey S Lee; Minh C Pham; Robert J Homer; Frank C Detterbeck; Inmaculada Aban; Leslie Jacobson; Angela Vincent; Richard J Nowak; Henry J Kaminski; Steven H Kleinstein; Kevin C O'Connor
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.